Cat. No.: HY-W342283

Diminazene

11 Cited Publications

Customer Review

Based on 11 publication(s) in Google Scholar

Diminazene is an antiparasitic agent widely used to treat parasitic diseases caused by hemoparasites (such as trypanosomes and babesia). Diminazene acts as an ACE2 activator and exerts cardiovascular protective effects by activating the ACE2/Ang-(1-7)/Mas receptor axis. By regulating gut microbiota-tryptophan metabolism, Diminazene inhibits the activation of core inflammatory signaling pathways including MAPK, STAT and NF-κB, increases central 5-HT levels, and suppresses splenic TNF-α production, thereby alleviating systemic inflammation.

For research use only. We do not sell to patients.

CAS No.: 536-71-0
Formula: C₁₄H₁₅N₇
Molecular Weight:281.32

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (277 KB)

Diminazene Chemical Structure

CAS No.: 536-71-0

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Publications (11)
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All Parasite Isoforms :

All Angiotensin Receptor Isoforms :

All p38 MAPK Isoforms :

All STAT Isoforms :

All NF-κB Isoforms :

All TNF Receptor Isoforms :

All 5-HT Receptor Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	IC₅₀	0.3 μM Compound: 1, Berenil	Inhibition of mouse hippocampal neurons ASIC transfected in CHO cells assessed as inhibition of acid-evoked current at -60 mV holding potential by two-electrode voltage-clamp electrophysiology assay Inhibition of mouse hippocampal neurons ASIC transfected in CHO cells assessed as inhibition of acid-evoked current at -60 mV holding potential by two-electrode voltage-clamp electrophysiology assay	[PMID: 24630693]
HEK293	IC₅₀	>80 μM Compound: Diminazene	Cytotoxicity against HEK239 cells after 72 hrs by Alamar blue assay Cytotoxicity against HEK239 cells after 72 hrs by Alamar blue assay	[PMID: 20558060]
L1210	IC₅₀	32 μM Compound: Berenil	Concentration required to inhibit the cell growth by 50 % after 48 hr in L1210 leukemic cells. Concentration required to inhibit the cell growth by 50 % after 48 hr in L1210 leukemic cells.	[PMID: 7658436]
L6	IC₅₀	5 μM Compound: Diminazene	Cytotoxicity against rat L6 cells after 70 hrs by alamar blue assay Cytotoxicity against rat L6 cells after 70 hrs by alamar blue assay	[PMID: 21112788]
OVCAR-3	GI₅₀	>25 μM Compound: DMZ	Antiproliferative activity against human OVCAR3 cells after 72 hrs by WST-1 assay Antiproliferative activity against human OVCAR3 cells after 72 hrs by WST-1 assay	[PMID: 27132164]

In Vitro

Diminazene downregulates lipopolysaccharide-induced proinflammatory cytokine production in macrophages by inhibiting the phosphorylation of MAPK/ERK and STAT proteins^[1].
Diminazene activates the ACE2/Ang (1-7)/Mas axis, thereby stimulating vascular repair-related functions in CD34⁺ cells^[1].
Diminazene (100 μM; 5 min) reduces non-induced arrhythmic contractions in isolated ventricular cardiomyocytes from C57bl6/J mice, while increasing the maximal contraction and relaxation rates, but exerts no effect on fractional shortening or systolic/diastolic duration parameters^[2].
Diminazene (100 μM; 5 min) shortens the action potential duration of all repolarization phases in isolated ventricular myocytes from C57bl6/J mice, induces resting membrane hyperpolarization, and inhibits the halothane+isoproterenol-induced prolongation of action potential, but exerts no effect on the action potential amplitude or the halothane-induced reduction in the maximum upstroke velocity of action potential^[2].
Diminazene inhibits the phosphorylation of MAPKs (ERK, p38, JNK), STAT1, STAT3 and NF-κB p65, while upregulating the expression of SOCS1 and SOCS3, and downregulating the production of proinflammatory cytokines in primary bone marrow-derived macrophages and dendritic cells without altering the expression of TLRs^[4].
Diminazene specifically binds to adenine-thymidine-rich sites in kinetoplast DNA of trypanosomes, induces irreversible akinetoplastic damage, disrupts chromatin structure during the G₂ phase of the cell cycle, and inhibits DNA replication by interfering with the binding of DNA topoisomerase and DNA conformation^[4].
Diminazene (3.12-200 μM; 24-120 h) potently kills immature cercariae of *Schistosoma mansoni* in a time- and concentration-dependent manner, with an EC₅₀ of 6.4 μM after 120 h of incubation^[6].
Diminazene (3.12-200 μM; 24-120 h) kills paired adult Schistosoma mansoni in a time- and concentration-dependent manner, with an EC₅₀ of 24.2 μM at 120 h^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Parmacokinetics

Species	Dose	Route	C_max	T_max	Plasma Concentration	T_1/2
Cattle^[1]	3.5 mg/kg	i.m.	4.76 μg/mL	0.5 h	0.43 μg/mL	61 h

In Vivo

Diminazene (5-15 mg/kg; i.v., p.o., s.c., single administration or long-term administration) exerts beneficial effects including reducing blood pressure, improving vascular endothelial and diastolic functions, protecting the heart and kidneys, regulating immunity, and inhibiting excessive inflammatory responses in various animal models of diseases^[1].
Diminazene (5 mg/kg; i.v.; single administration) reduces halothane-epinephrine induced arrhythmic events in rats by approximately 68%, and its effect is independent of Mas receptor activation and nitric oxide release^[2].
Diminazene (15 mg/kg; s.c.; single administration) non-significantly reduces the 48-hour mortality rate to 38.5% in a rat model of septic cardiomyopathy, improves cardiac function, decreases the levels of inflammatory and myocardial injury biomarkers, restores the balance of the myocardial renin-angiotensin system, and alleviates myocardial structural damage^[3].
Diminazene modulates host immune responses, reduces the production of proinflammatory cytokines, controls parasitemia, enhances the production of parasite-specific antibodies, and induces protective immunity against homologous Trypanosoma congolense challenge in infected mice^[4].
Pretreatment with Diminazene inhibits LPS (HY-D1056)-induced production of proinflammatory cytokines by suppressing the phosphorylation of MAPK and STAT and upregulating SOCS proteins, thereby ameliorating acute inflammation and mortality in LPS-challenged mice^[4].
Chronic administration of Diminazene prevents and blocks experimental pulmonary hypertension, and upregulates the expression of ACE II mRNA in rats treated with Bleomycin (HY-108345) and Monocrotaline (HY-N0750)^[4].
Diminazene (2 mg/kg; i.p.; single administration) reduces the production of TNF in serum and spleen by restoring intestinal ACE2 function, elevating central 5-HT levels, and activating the efferent sympathetic branch of the inflammatory reflex, thereby alleviating systemic inflammatory responses in male C57BL/6 mice with endotoxemia^[5].
Diminazene (10-400 mg/kg; i.p., p.o.; single administration) reduces worm burden, egg production, hepatosplenomegaly severity and liver injury markers in mice with chronic S. mansoni infection in a dose- and route-dependent manner, with an ED₅₀ of 44.6 mg/kg for intraperitoneal injection and 226.8 mg/kg for oral administration^[6].
Diminazene (100-400 mg/kg; i.p., p.o.; single administration) causes a significant moderate reduction in worm burden in mice with early-stage Schistosoma mansoni infection, while reducing egg production, but fails to alleviate hepatosplenomegaly in this model^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Wistar rats (male)^[2]
Dosage:

5 mg/kg
Administration:

i.v.; single injection
Result:

Reduced arrhythmic events.
Maintained antiarrhythmic effect when co-administered with Mas receptor blocker A-779 or nitric oxide synthase inhibitor L-NAME.

Animal Model:

Wistar rats (male, 10-11 weeks old, 280-320 g, cecal ligation and puncture surgery)^[3]
Dosage:

15 mg/kg
Administration:

s.c.; single dose 30 minutes pre-surgery
Result:

Mitigated the development of SCM and preserve cardiac function during sepsis possibly by interfering with the renin-angiotensin system through promoting myocardial ACE2 expression and restoring local Ang-(1-7) levels.

Chemical Information

CAS No. 536-71-0
Molecular Weight 281.32
Formula C₁₄H₁₅N₇
SMILES

N=C(C1=CC=C(C=C1)/N=N/NC2=CC=C(C(N)=N)C=C2)N
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (11)

All Bio/Physico-chemical AssayIHCRT-PCRIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Cell Metab

Imatinib and methazolamide ameliorate COVID-19-induced metabolic complications via elevating ACE2 enzymatic activity and inhibiting viral entry. [Abstract]

2022 Mar 1;34(3):424-440.e7. PMID: 35150639

Diminazene purchased from MedChemExpress. Usage Cited in: Cell Metab. 2022 Mar 1;34(3):424-440.e7. [Abstract]

The direct binding was illustrated by surface plasmon resonance (SPR) assay of purified ACE2 protein with Diminazene aceturate (DIZE;0.125, 0.25, 0.5, 1, 2 μM).

Diminazene purchased from MedChemExpress. Usage Cited in: Cell Metab. 2022 Mar 1;34(3):424-440.e7. [Abstract]

HUVECs were treated with Diminazene aceturate (DIZE, 100 μM), imatinib (Ima), harpagoside (Har) or methazolamide (Met) for 16 h and subjected to real-time PCR
Int J Radiat Oncol Biol Phys

Activation of Angiotensin Converting Enzyme 2 (ACE2) Mitigates Gastrointestinal Acute Radiation Syndrome (GI-ARS). [Abstract]

2025 Sep 16:S0360-3016(25)06272-8. PMID: 40967372

Diminazene purchased from MedChemExpress. Usage Cited in: Int J Radiat Oncol Biol Phys. 2025 Sep 16:S0360-3016(25)06272-8. [Abstract]

Diminazene aceturate (DIZE; 15 mg/kg; SC）showed a near depletion of Ki-67+ regenerating intestinal crypts. WAG/RijCmcr rats were exposed to 12.5 Gy PBI and treated subcutaneously with vehicle or Diminazene aceturate (DIZE; 15 mg/kg; SC on days 3, 4, and 5 postirradiation. Representative Ki-67-stained IHC cross-sections of day 6 jejunum from nonirradiated, 12.5 Gy + vehicle-treated, or 12.5 Gy + DIZE.

Diminazene purchased from MedChemExpress. Usage Cited in: Int J Radiat Oncol Biol Phys. 2025 Sep 16:S0360-3016(25)06272-8. [Abstract]

Diminazene aceturate (DIZE; 15 mg/kg; SC）showed a decrease in plasma citrulline levels indicative of reduced GI mass in WAG/RijCmcr rats. Mean plasma citrulline levels at day 6 in female and male rats after irradiation and treatment with vehicle or DIZE.

Diminazene purchased from MedChemExpress. Usage Cited in: Int J Radiat Oncol Biol Phys. 2025 Sep 16:S0360-3016(25)06272-8. [Abstract]

Diminazene aceturate (DIZE; 15 mg/kg; SC) increased luminal ACE2 staining. Representative ACE2-stained IHC cross-sections of day 6 jejunums from nonirradiated, 12.5 Gy + vehicle-treated, or 12.5 Gy + DIZE.
Drug Deliv Transl Res

Leveraging quantum chemical properties in transfer learning for predicting blood-brain barrier permeability of drugs. [Abstract]

2025 Oct 29. PMID: 41160380
Int Immunopharmacol

ACE2/Ang(1-7)/MasR axis exerts protective effects on lung ischemia/reperfusion injury via NF-κB-dependent mitochondrial adaptation and epithelial cell pyroptosis. [Abstract]

2025 Aug 11:164:115325. PMID: 40795499
Neuropharmacology

Diminazene attenuates astrocytic oxidative stress and neuronal ferroptosis via miR-10b-3p/NOX4 axis in Alzheimer's Disease Model. [Abstract]

2026 May 15:289:110880. PMID: 41698644
FASEB J

Diminazene Aceturate Ameliorates Hypertension-Induced Cognitive Impairment by Disrupting the CCN1-Integrin αvβ6-TGF-β Axis and Preserving Mitochondrial Integrity. [Abstract]

2026 Mar 31;40(6):e71682. PMID: 41860098
J Inflamm Res

Diminazene Ameliorates Neuroinflammation by Suppression of Astrocytic miRNA-224-5p/NLRP3 Axis in Alzheimer's Disease Model. [Abstract]

2023 Apr 17:16:1639-1652. PMID: 37092127
Endocrine

A potential impact of SARS-CoV-2 on pituitary glands and pituitary neuroendocrine tumors. [Abstract]

2021 May;72(2):340-348. PMID: 33786714
Radiat Res

Mitigation of Multi-Organ Radiation Injury with ACE2 Agonist Diminazene Aceturate. [Abstract]

2022 Oct 1;198(4):325-335. PMID: 35904437
Parasitol Res

Furamidine, a methyltransferase inhibitor, is a potential anti-Babesia spp. chemotherapeutic. [Abstract]

2025 Dec 3;124(12):149. PMID: 41339613
Research Square Preprint

2021 Mar.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Qaradakhi T, et al. The potential actions of angiotensin-converting enzyme II (ACE2) activator diminazene aceturate (DIZE) in various diseases. Clin Exp Pharmacol Physiol. 2020;47(5):751-758. [Content Brief]

[2]. Joviano-Santos JV, et al. Diminazene aceturate (DIZE) has cellular and in vivo antiarrhythmic effects. Clin Exp Pharmacol Physiol. 2020;47(2):213-219. [Content Brief]

[3]. Lu Z, et al. Diminazene aceturate mitigates cardiomyopathy by interfering with renin-angiotensin system in a septic rat model. BMC Pharmacol Toxicol. 2022;23(1):44. Published 2022 Jul 4. [Content Brief]

[4]. Kuriakose S, et al. Diminazene aceturate (Berenil), a new use for an old compound?. Int Immunopharmacol. 2014;21(2):342-345. [Content Brief]

[5]. Passaglia P, et al. Diminazene aceturate attenuates systemic inflammation via microbiota gut-5-HT brain-spleen sympathetic axis in male mice. Brain Behav Immun. 2024;119:105-119. [Content Brief]

[6]. de Brito MG, et al. Therapeutic Effect of Diminazene Aceturate on Parasitic Blood Fluke Schistosoma mansoni Infection. Antimicrob Agents Chemother. 2020;64(11):e01372-20. Published 2020 Oct 20. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Diminazene

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Diminazene

All Parasite Isoforms

All Angiotensin Receptor Isoforms

All p38 MAPK Isoforms

All STAT Isoforms

All NF-κB Isoforms

All TNF Receptor Isoforms

All 5-HT Receptor Isoforms

Biological Activity

Chemical Information

Publications (11)

Purity & Documentation

References

Calculators

Help & FAQs

Diminazene

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Diminazene

All Parasite Isoforms

All Angiotensin Receptor Isoforms

All p38 MAPK Isoforms

All STAT Isoforms

All NF-κB Isoforms

All TNF Receptor Isoforms

All 5-HT Receptor Isoforms

Biological Activity

Chemical Information

Publications (11)

Purity & Documentation

References

Calculators

Help & FAQs

Diminazene Related Classifications

Cat. No.: HY-W342283